Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lung | Lung Cancer

FDA Approves Optune Luna for Metastatic NSCLC

Posted on October 21, 2024
Post Views: 121

Lung | Lung CancerU.S. based FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for treatment of patients with metastatic non-small cell lung cancer and whose disease has progressed on or after platinum-based regimen. This approval is based on the LUNAR Phase 3 study. The patients with Optune Lua realized a notable improvement in overall conditions in comparison to patients with standard therapy only. Optune Lua is a wearable device for which tumor-treating fields inhibit proliferation and metastasis of lung cancer cells. In this method, it utilizes low intensity and different frequencies. This approval by FDA has opened up the potential of this treatment for NSCLC patients.

This wearable treatment delivers Tumor Treating Fields which exert physical forces on the electrically charged components of dividing cancer cells and this results in cell death.

Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a new and urgently needed option for people with metastatic NSCLC who have progressed while on or after platinum-based chemotherapy,” said Asaf Danziger, CEO, Novocure. “We are grateful to the patients, caregivers, investigators and healthcare providers who supported the clinical trials that led to this approval.”

The results of the study showed a statistically significant improvement in OS with addition of concurrent Optune Lua. It met a prespecified secondary endpoint showing addition of Optun3 Lua to PD-1/PD-L1 inhibitor therapy conferred significant improvement in OS. The overall survival rates observed with Optune Lua in LUNAR study mark the first substantial improvement in over eight years in this patient population, making it a compelling development for many patients.

The information shared in this blog is for educational purposes only. You should always consult with your healthcare provider for any medical needs.

Subscribe to our newsletter or follow us on Facebook or Twitter today to stay informed and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,322)
  • Lung Cancer: Symptoms and Treatment (5,652)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025
  • Lung Cancer Screening Is Beneficial For Non-Smokers As Well April 28, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d